GlobeNewswire
Netherton Syndrome Pipeline: Industry Insights into Global emerging therapies scenario, Leading Pharma Players, Emerging Trends | DelveInsight
Netherton Syndrome Pipeline Insight represents a class of promising therapies for a rare and severe genetic skin disease. With a significant understanding of genetic defects and pathophysiological mechanisms of Netherton Syndrome, companies are exploring new molecules.Los Angeles, USA, May 13, 2021 (GLOBE NEWSWIRE) — Netherton Syndrome Pipeline: Industry Insights into Global emerging therapies scenario, Leading Pharma Players, Emerging Trends | DelveInsight Netherton Syndrome Pipeline Insight represents a class of promising therapies for a rare and severe genetic skin disease. With a significant understanding of genetic defects and pathophysiological mechanisms of Netherton Syndrome, companies are exploring new molecules. DelveInsight’s ‘Netherton Syndrome Pipeline Insights’ report draws a complete picture of the Netherton Syndrome pipeline therapies that are under development in pre-clinical as well as different clinical stages of development along with discontinued products and growth prospects across the Netherton Syndrome landscape. Key takeaways from the Netherton Syndrome Pipeline report: Netherton Syndrome Pipeline report offers a comprehensive analysis of 10+ key players and10+ key therapies.Netherton Syndrome pipeline comprises BBP-561 (BridgeBio Pharma), LM-030 (LifeMax Laboratories), KB104 (Krystal Biotech), TMB-001 (Timber Pharmaceuticals), ATR-12 (Azitra), and others. Out of all the emerging therapies, late-stage products such as LM-030, a topical treatment for Netherton Syndrome, are expected to transform the treatment market.LM-030 is currently in Phase II/III pivotal clinical trial development by LifeMax Laboratories. In April 2020, the US Food and Drug Administration (FDA) granted fast track designation to LM-030.LM-030 previously received orphan drug designation (ODD) from both the FDA and European Commission as well as rare pediatric disease designation (RPD) from the FDA. Request for Sample @ Netherton Syndrome Emerging Therapies and Forecast to learn more about the emerging therapy having an advantage Netherton Syndrome: Overview Netherton syndrome (NS) is a rare autosomal recessive disease, characterized by congenital ichthyosis, trichorrhexis invaginata, erythroderma, atopic manifestations, high immunoglobulin E levels, hypereosinophilia, and failure to thrive. The Netherton Syndrome pipeline report offers a rich coverage of therapeutics by development stage, product type, and route of administration, molecule type, and MOA type for Netherton Syndrome across the complete product development cycle, including all clinical and non-clinical stages. Netherton Syndrome Pipeline Drug Portfolio DrugCompanyClinical PhaseMoARoALM-030 LifeMax LaboratoriesPhase II/IIIKallikrein-related peptidase inhibitorsTopicalTMB-001Timber PharmaceuticalsPhase IIRetinoic acid receptor agonistsTopicalMSB-6005MatriSys BioPhase IMicrobiome modulatorsTopicalKB104 Krystal BiotechPreclinicalGene transferenceNAATR-12 AzitraPreclinicalSerine peptidase inhibitor kazal-type 5 replacementsTopicalBBP-561 BridgeBio PharmaPreclinicalKallikrein 5/7 inhibitorsTopical Request for Sample to know which drug is expected to outperform @ Netherton Syndrome Pipeline Analysis, Key Companies, and Futuristic Trends Netherton Syndrome Therapeutics Assessment The Netherton Syndrome Pipeline report proffers exhaustive insights into active Netherton Syndromepipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs. By Product Type MonoCombination By Stage Discovery Pre-clinicalINDPhase IPhase IIPhase IIIPre-registration By Molecule Type Small Molecule Gene TherapyImmunoglobulin fragmentsMonoclonal antibodiesSkin disorder therapies By Route of Administration IntravitrealTopicalOralSubcutaneous By Mechanism of Action Gene transferenceKallikrein-related peptidase inhibitorsMicrobiome modulatorsSerine peptidase inhibitor kazal-type 5 replacements By Targets Kallikrein-related peptidaseRetinoic acid receptorSerine peptidase inhibitor kazal-type 5KallikreinSerine endopeptidase By Stage and Route of AdministrationBy Stage and Product Type Get in touch with our Business executive for Comprehensive Regulatory Analysis of Pipeline Therapies The Netherton Syndrome pipeline report puts on the table business opportunities, threats, prospective collaborations, strong competitors, growth strategies, and failed as well as discontinued drugs that will help the clients to keep a track of the ongoing trials, recent happenings in the domain. For more information on emerging drugs, visit Netherton Syndrome Pipeline Analysis Scope of the Report Coverage: GlobalKey Players: LifeMax Laboratories, Timber Pharmaceuticals, MatriSys Bio, Krystal Biotech, Azitra, BridgeBio Pharma, Dermelix Biotherapeutics, and many more.Key Netherton Syndrome Pipeline Therapies: LM-030, TMB-001, MSB-6005, KB104, ATR-12, BBP-561, DMX-102, and many more. Reach out @ Netherton Syndrome Pipeline: Novel therapies and emerging trends Table of Contents 1Introduction2Executive Summary3Netherton Syndrome Overview4Netherton Syndrome Pipeline Therapeutics5Netherton Syndrome Pipeline Therapeutic Assessment6Netherton Syndrome – DelveInsight’s Analytical Perspective7In-depth Commercial Netherton Syndrome Pipeline Assessment8Netherton Syndrome Collaboration Deals9Late Stage Netherton Syndrome Pipeline Products (Phase III and Preregistration)10Mid-Stage Netherton Syndrome Pipeline Products (Phase II)11Pre-clinical and Discovery Stage Netherton Syndrome Pipeline Products12Inactive Netherton Syndrome Pipeline Products13Netherton Syndrome Key Companies14Netherton Syndrome Key Products15Netherton Syndrome Unmet Needs16Netherton Syndrome Market Drivers and Barriers17Netherton Syndrome Future Perspectives and Conclusion18Netherton Syndrome Pipeline Analyst Views20Appendix Visit to know more of what’s covered @ Netherton Syndrome Emerging Therapies Related Reports Netherton Syndrome MarketDelveInsight’s “Netherton Syndrome – Market Insights, Epidemiology, and Market Forecast-2030” report. Netherton Syndrome Epidemiology ForecastDelveInsight’s ‘Netherton Syndrome – Epidemiology Forecast to 2030’ report.Multiple Myeloma MarketDelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030’ report. Acquired Hemophilia A MarketDelveInsight’s “Acquired Hemophilia A Market Insights, Epidemiology, and Market Forecast-2030” report. Acromegaly MarketDelveInsight’s ‘Acromegaly-Market Insights, Epidemiology, and Market Forecast–2030’ report. Adenoid Cystic Carcinom MarketDelveInsight’s “Adenoid Cystic Carcinom – Market Insights, Epidemiology, and Market Forecast-2030” report. Allergic Bronchopulmonary Aspergillosis MarketDelveInsight’s “Allergic Bronchopulmonary Aspergillosis – Market Insights, Epidemiology, and Market Forecast-2030” report. Related Posts Alagille Syndrome MarketChallenges in the Rare Disease MarketRare Cancer MarketAngelman Syndrome Medications About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
Recent Comments